These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

890 related articles for article (PubMed ID: 20587519)

  • 1. Nrdp1-mediated regulation of ErbB3 expression by the androgen receptor in androgen-dependent but not castrate-resistant prostate cancer cells.
    Chen L; Siddiqui S; Bose S; Mooso B; Asuncion A; Bedolla RG; Vinall R; Tepper CG; Gandour-Edwards R; Shi X; Lu XH; Siddiqui J; Chinnaiyan AM; Mehra R; Devere White RW; Carraway KL; Ghosh PM
    Cancer Res; 2010 Jul; 70(14):5994-6003. PubMed ID: 20587519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcription of Nrdp1 by the androgen receptor is regulated by nuclear filamin A in prostate cancer.
    Savoy RM; Chen L; Siddiqui S; Melgoza FU; Durbin-Johnson B; Drake C; Jathal MK; Bose S; Steele TM; Mooso BA; D'Abronzo LS; Fry WH; Carraway KL; Mudryj M; Ghosh PM
    Endocr Relat Cancer; 2015 Jun; 22(3):369-86. PubMed ID: 25759396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ErbB family and androgen receptor signaling are targets of Celecoxib in prostate cancer.
    Brizzolara A; Benelli R; Venè R; Barboro P; Poggi A; Tosetti F; Ferrari N
    Cancer Lett; 2017 Aug; 400():9-17. PubMed ID: 28450158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen receptor variants occur frequently in castration resistant prostate cancer metastases.
    Zhang X; Morrissey C; Sun S; Ketchandji M; Nelson PS; True LD; Vakar-Lopez F; Vessella RL; Plymate SR
    PLoS One; 2011; 6(11):e27970. PubMed ID: 22114732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth.
    Yen L; Cao Z; Wu X; Ingalla ER; Baron C; Young LJ; Gregg JP; Cardiff RD; Borowsky AD; Sweeney C; Carraway KL
    Cancer Res; 2006 Dec; 66(23):11279-86. PubMed ID: 17145873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors.
    Mitsiades N; Sung CC; Schultz N; Danila DC; He B; Eedunuri VK; Fleisher M; Sander C; Sawyers CL; Scher HI
    Cancer Res; 2012 Dec; 72(23):6142-52. PubMed ID: 22971343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth.
    Guo Z; Yang X; Sun F; Jiang R; Linn DE; Chen H; Chen H; Kong X; Melamed J; Tepper CG; Kung HJ; Brodie AM; Edwards J; Qiu Y
    Cancer Res; 2009 Mar; 69(6):2305-13. PubMed ID: 19244107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen receptor transcriptional activity is required for heregulin-1β-mediated nuclear localization of the HER3/ErbB3 receptor tyrosine kinase.
    Jathal MK; Siddiqui S; Vasilatis DM; Durbin Johnson BP; Drake C; Mooso BA; D'Abronzo LS; Batra N; Mudryj M; Ghosh PM
    J Biol Chem; 2023 Aug; 299(8):104973. PubMed ID: 37380074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unique targeting of androgen-dependent and -independent AR signaling in prostate cancer to overcome androgen resistance.
    Lim SC; Jansson PJ; Assinder SJ; Maleki S; Richardson DR; Kovacevic Z
    FASEB J; 2020 Sep; 34(9):11511-11528. PubMed ID: 32713076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of sLZIP in cyclin D3-mediated negative regulation of androgen receptor transactivation and its involvement in prostate cancer.
    Kim Y; Kim J; Jang SW; Ko J
    Oncogene; 2015 Jan; 34(2):226-36. PubMed ID: 24441043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Compensatory upregulation of tyrosine kinase Etk/BMX in response to androgen deprivation promotes castration-resistant growth of prostate cancer cells.
    Dai B; Chen H; Guo S; Yang X; Linn DE; Sun F; Li W; Guo Z; Xu K; Kim O; Kong X; Melamed J; Qiu S; Chen H; Qiu Y
    Cancer Res; 2010 Jul; 70(13):5587-96. PubMed ID: 20570899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen-dependent regulation of Her-2/neu in prostate cancer cells.
    Berger R; Lin DI; Nieto M; Sicinska E; Garraway LA; Adams H; Signoretti S; Hahn WC; Loda M
    Cancer Res; 2006 Jun; 66(11):5723-8. PubMed ID: 16740710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.
    Hu R; Lu C; Mostaghel EA; Yegnasubramanian S; Gurel M; Tannahill C; Edwards J; Isaacs WB; Nelson PS; Bluemn E; Plymate SR; Luo J
    Cancer Res; 2012 Jul; 72(14):3457-62. PubMed ID: 22710436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Y-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expression.
    Shiota M; Takeuchi A; Song Y; Yokomizo A; Kashiwagi E; Uchiumi T; Kuroiwa K; Tatsugami K; Fujimoto N; Oda Y; Naito S
    Endocr Relat Cancer; 2011 Aug; 18(4):505-17. PubMed ID: 21652770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A COP1-GATA2 axis suppresses AR signaling and prostate cancer.
    Shen T; Dong B; Meng Y; Moore DD; Yang F
    Proc Natl Acad Sci U S A; 2022 Oct; 119(43):e2205350119. PubMed ID: 36251994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dominant-negative androgen receptor inhibition of intracrine androgen-dependent growth of castration-recurrent prostate cancer.
    Titus MA; Zeithaml B; Kantor B; Li X; Haack K; Moore DT; Wilson EM; Mohler JL; Kafri T
    PLoS One; 2012; 7(1):e30192. PubMed ID: 22272301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen Receptor Regulation of Local Growth Hormone in Prostate Cancer Cells.
    Recouvreux MV; Wu JB; Gao AC; Zonis S; Chesnokova V; Bhowmick N; Chung LW; Melmed S
    Endocrinology; 2017 Jul; 158(7):2255-2268. PubMed ID: 28444169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen receptor as a regulator of ZEB2 expression and its implications in epithelial-to-mesenchymal transition in prostate cancer.
    Jacob S; Nayak S; Fernandes G; Barai RS; Menon S; Chaudhari UK; Kholkute SD; Sachdeva G
    Endocr Relat Cancer; 2014 Jun; 21(3):473-86. PubMed ID: 24812058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-transcriptional mechanisms contribute to the suppression of the ErbB3 negative regulator protein Nrdp1 in mammary tumors.
    Ingalla EQ; Miller JK; Wald JH; Workman HC; Kaur RP; Yen L; Fry WH; Borowsky AD; Young LJ; Sweeney C; Carraway KL
    J Biol Chem; 2010 Sep; 285(37):28691-7. PubMed ID: 20628057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual EGFR/HER2 inhibition sensitizes prostate cancer cells to androgen withdrawal by suppressing ErbB3.
    Chen L; Mooso BA; Jathal MK; Madhav A; Johnson SD; van Spyk E; Mikhailova M; Zierenberg-Ripoll A; Xue L; Vinall RL; deVere White RW; Ghosh PM
    Clin Cancer Res; 2011 Oct; 17(19):6218-28. PubMed ID: 21844010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.